{"filings":[{"id":860880,"accession_number":"0001193125-26-257365","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2026-06-04T20:05:16+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Trevi Therapeutics stockholders approve doubling of authorized shares to 400M and 8M share increase in stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Michael Heffernan as Class I director for a term expiring at the 2029 annual meeting.","Ratified Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.","Advisory vote approved compensation of named executive officers with 98.1M for vs. 2.0M against.","Approved Amended and Restated 2019 Stock Incentive Plan, increasing shares available by 8M.","Approved Certificate of Amendment to double authorized common stock from 200M to 400M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93676,"accession_number":"0001193125-26-206382","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics reports Q1 net loss $13.2M; cash runway extended to 2030 after $162M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M in Q1 2026 vs $10.3M YoY; R&D expenses $9.9M, G&A $5.0M.","Cash, equivalents and marketable securities $171.8M at March 31; April offering net ~$162M.","FDA alignment on Phase 3 plan for Haduvio in IPF-related chronic cough; first Phase 3 starts Q2 2026.","Phase 2b in refractory chronic cough starts Q2 2026; Phase 2b in non-IPF ILD cough starts H2 2026.","European patent granted for nalbuphine ER in IPF cough, expiration 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93675,"accession_number":"0001193125-26-160355","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Trevi Therapeutics prices $150M stock offering; provides Haduvio trial updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11.6M shares at $13.00/sh; net proceeds ~$141.1M (or ~$162.4M if option exercised).","Cash, cash equivalents and marketable securities ~$171.8M as of March 31, 2026.","Cash runway extended through 2029, funding two Phase 3 IPF-cough trials and Phase 2b in non-IPF ILD and RCC.","First Phase 3 IPF trial starts Q2 2026; topline results expected H1 2028; second Phase 3 in H2 2026 with results H2 2027.","Phase 2b for RCC begins Q2 2026, topline results H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105494,"accession_number":"0001193125-26-110767","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.","Cash, cash equivalents $188.3M at year-end 2025; expected runway into 2028.","Q4 2025 net loss $8.3M vs $11.4M in Q4 2024; FY2025 net loss $42.8M.","R&D expenses Q4 $6.2M down from $9.3M; G&A $4.0M up from $2.9M.","Plan to initiate Phase 2b trial for refractory chronic cough in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105493,"accession_number":"0001193125-26-098676","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics gains FDA alignment on Phase 3 plan for nalbuphine ER in IPF cough; first trial Q2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["End-of-Phase 2 FDA meeting: overall alignment on IPF-related chronic cough development program including two pivotal Phase 3 trials and Phase 1 studies for NDA support.","First Phase 3 trial (~300 patients, 52-week dosing, primary endpoint at 24 weeks) expected to start Q2 2026; second Phase 3 (~130 patients, 12-week dosing) in H2 2026.","Both trials randomized, double-blind, placebo-controlled, global, evaluating nalbuphine ER 54 mg BID vs placebo with 2:1 randomization.","Primary endpoint for both: relative change from baseline in 24-hour cough frequency measured by objective cough monitor.","Trial designs are subject to final FDA protocol review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121771,"accession_number":"0001193125-25-308769","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).","Base salary set at $522,000; annual bonus target up to 40% of base salary.","Receives option to purchase 375,000 shares, vesting 25% on first anniversary and monthly thereafter.","Eligible for separation benefits under the Executive Separation Benefits and Retention Plan.","Standard indemnification agreement to be entered with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121770,"accession_number":"0001193125-25-280149","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.","Cash and marketable securities $194.9M at Sept 30, 2025; expected runway into 2028.","Preparing End-of-Phase 2 meeting request to FDA for IPF chronic cough in Q4 2025.","Phase 3 program for IPF chronic cough planned to start in H1 2026.","Phase 2b study for refractory chronic cough (RCC) also targeted for H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138444,"accession_number":"0001563880-25-000005","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Trevi Therapeutics CFO Lisa Delfini to depart Aug 22; CEO to serve as interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.","CEO Jennifer L. Good will serve as interim principal financial officer until a permanent CFO is appointed.","Delfini will receive separation benefits under the Executive Separation Benefits and Retention Plan, subject to a severance and release agreement.","No details provided on search for permanent CFO or timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138443,"accession_number":"0000950170-25-105011","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).","LCQ Total Score increased 3.4 points (108 mg) and 3.7 points (54 mg); 1.3-point increase is clinically meaningful.","Completed $115M underwritten offering; cash and securities $203.9M, runway into 2029.","R&D expenses $9.4M (down from $10.0M); G&A $4.3M (up from $3.3M); net loss $12.3M.","Plans to request End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 start expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155907,"accession_number":"0000950170-25-087486","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Trevi shareholders approve 6M share increase for 2019 Stock Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted to increase authorized shares under the 2019 Plan by 6,000,000 shares.","Class III directors Jennifer Good and Anne VanLent re-elected with 78.8M and 62.9M votes for, respectively.","Ratification of Ernst & Young as auditor for FY2025 passed with 88.9M votes for.","Advisory say-on-pay approved (78.3M for, 0.7M against); future votes will be held every year.","All proposals, including the equity plan amendment, received required majority approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155906,"accession_number":"0001193125-25-134913","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Trevi Therapeutics prices $100M common stock offering at $5.75 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17.4M shares at $5.75/share; net proceeds ~$93.7M (~$107.8M if underwriters' option fully exercised).","Underwriters granted 30-day option to purchase up to 2.61M additional shares at the same price.","Proceeds to fund clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC.","Cash runway extended into 2029 based on current plans; additional capital needed for regulatory approval.","Offering expected to close on June 5, 2025; Morgan Stanley, Leerink, Stifel, Cantor as joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155905,"accession_number":"0001193125-25-133273","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.","Sales Agreement remains in effect; no sales permitted until a new prospectus is filed.","As of March 31, 2025, Trevi sold 4,498,065 shares for gross proceeds of ~$14.6M.","No shares issued or sold under the Sales Agreement after March 31, 2025.","Commissions and fees on past sales totaled approximately $0.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155904,"accession_number":"0001193125-25-132890","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics reports positive Phase 2b topline results for Haduvio in IPF chronic cough","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 60.2% reduction in 24-hour cough frequency at 108 mg BID (p<0.0001) vs 16.9% placebo.","Statistically significant improvements on cough-severity NRS and E-RS:IPF Cough Subscale at 108 mg and 54 mg BID.","Discontinuation due to AEs similar between Haduvio (5.6%) and placebo (5.0%); safety profile consistent with prior trials.","Expects end-of-Phase 2 FDA meeting in H2 2025; plans Phase 2b trial in refractory chronic cough starting H1 2026.","Also plans to initiate clinical trial of Haduvio for non-IPF interstitial lung disease cough in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155903,"accession_number":"0000950170-25-066971","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.","RIVER Phase 2a positive: 67% cough reduction from baseline, 57% placebo-adjusted (p<0.0001).","CORAL Phase 2b enrollment completed Feb 2025; last patient visit Apr 2025; topline results on track for Q2 2025.","Cash, equivalents and marketable securities $103.3M; runway expected into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174359,"accession_number":"0000950170-25-041187","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics Reports Q4 and Full Year 2024 Financial Results and Provides Positive Clinical Updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.","Completed enrollment in Phase 2b CORAL trial in IPF patients with chronic cough, topline data expected Q2 2025.","Sample size re-estimation for CORAL trial reaffirmed original sample size of 160 patients.","Ended 2024 with $107.6 million cash, expected runway into H2 2026.","Net loss for 2024 was $47.9 million, compared to $29.1 million in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174358,"accession_number":"0000950170-25-036503","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi's Haduvio meets Phase 2a RIVER primary endpoint; 57% placebo-adjusted cough reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: 67% reduction from baseline in 24-hour cough frequency; 57% placebo-adjusted (p<0.0001).","84% of Haduvio patients had ≥30% reduction vs 29% placebo; early response at Day 7 (27 mg BID).","Severe cough subgroup (20+ coughs/hr): 66% reduction; moderate (10-19/hr): 68% reduction (p<0.0001).","Safety profile consistent with prior Haduvio trials; no treatment-emergent serious adverse events.","Trevi plans to discuss results with FDA and initiate next study after FDA input."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174357,"accession_number":"0000950170-25-003286","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.","Last patient completed final visit in Phase 2a RIVER trial (RCC); topline results expected Q1 2025.","Phase 2b CORAL trial (IPF chronic cough) now ~80% enrolled after positive SSRE; topline expected H1 2025.","SSRE analysis in Dec 2024 reaffirmed original sample size of N=160 for CORAL trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191316,"accession_number":"0001193125-24-279715","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.","Participants include Adage Capital, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital, Vivo Capital.","Expected to close on December 17, 2024, subject to customary conditions.","Company developing Haduvio for chronic cough in IPF and refractory chronic cough.","Leerink Partners, Stifel, and Oppenheimer are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191315,"accession_number":"0000950170-24-135602","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics reports positive SSRE for Phase 2b CORAL trial; sample size unchanged at 160 patients.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SSRE analysis on highest 108mg BID dose after 80 patients completed 6 weeks recommended continuing as planned; no sample size increase or futility.","Trial enrollment 75% complete; topline results from CORAL Phase 2b still expected in first half of 2025.","Pre-specified conditional power maintained at 80% or greater based on SSRE outcome.","Other two pre-specified SSRE outcomes (sample size increase or futility) were ruled out."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191314,"accession_number":"0000950170-24-132883","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics announces positive HAP study results for oral nalbuphine; primary endpoint met at clinical doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: mean Emax for 'Drug Liking' for oral nalbuphine 81mg was 71.2 vs IV butorphanol 6mg (82.3), p<0.0001.","Oral nalbuphine 162mg also statistically significant (74.5 vs 82.3, p=0.0008); 486mg supratherapeutic dose not significant (p=0.3221).","No serious adverse events reported; secondary endpoints (e.g., 'Take Drug Again,' 'I Feel High') consistent with primary result.","Results will be included in 8-factor abuse potential analysis for nalbuphine ER as part of planned NDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191313,"accession_number":"0000950170-24-122316","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.","Cash, cash equivalents and marketable securities of $65.5M at quarter end; expected runway into H2 2026.","Completed enrollment in Phase 2a RIVER trial for refractory chronic cough; topline results expected Q1 2025.","Enrolled 50% of planned 160 patients in Phase 2b CORAL trial for chronic cough in IPF; SSRE outcome expected Dec 2024; topline H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191312,"accession_number":"0000950170-24-115800","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).","The trial is evaluating Haduvio for the treatment of refractory chronic cough.","Topline data from the RIVER trial is expected to be reported in the first quarter of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191311,"accession_number":"0000950170-24-112729","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trevi Therapeutics updates pipeline timelines: CORAL at 50% enrolled, SSRE in Dec, RIVER topline Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b CORAL trial for chronic cough in IPF enrolled 50% of target (N=160); SSRE expected December 2024.","SSRE may maintain current size, upsize within pre-specified range, or evaluate for futility; topline H1 2025 if unchanged.","Human Abuse Potential study completed dosing; topline results expected December 2024.","Phase 2a RIVER trial for refractory chronic cough enrolled planned sample size; topline results now expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191310,"accession_number":"0000950170-24-110462","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.","David Clark stepped down as CMO effective Sept 27, 2024, to care for a family member; will consult at $400/hour.","Cassella has 35+ years CNS drug development experience, including CDO at Concert Pharmaceuticals and FDA approval of Leqselvi.","Company is advancing Haduvio for IPF cough and refractory chronic cough; pivotal program and regulatory submission planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207790,"accession_number":"0000950170-24-093942","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.","Cash and equivalents $69.5M; cash runway expected into 2026.","Phase 2a RIVER trial (RCC) ~80% enrolled; topline data expected Q4 2024.","Phase 2b CORAL trial (IPF cough) sample size re-estimation expected Q4 2024; topline H1 2025.","Appointed Margaret Garin, MD, MSCR as VP of Clinical Development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225268,"accession_number":"0000950170-24-073129","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Trevi Therapeutics annual meeting results: all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dominick Colangelo re-elected as Class II director with 47.1M votes for (99.8% of votes cast).","Edward Mathers re-elected with 32.7M for; David Meeker re-elected with 33.6M for.","Ernst & Young ratified as independent auditor for FY2024 with 54.0M for (99.9% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225267,"accession_number":"0000950170-24-054478","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.","Cash, equivalents and marketable securities $72.8M; runway expected into 2026.","Phase 2a RIVER trial in RCC fully enrolled? all sites activated; topline data expected H2 2024.","Phase 2b CORAL trial in IPF chronic cough enrolling ~160 pts; topline data H1 2025.","HAP study 75% enrolled; IND cleared for Phase 1b respiratory physiology trial starting Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244470,"accession_number":"0000950170-24-034159","cik":1563880,"company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.","Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.","Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.","Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.","Human Abuse Potential study over 50% enrolled; topline data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2055866113.1183393,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}